Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

7.79B

Market cap7.79B

Price-Earnings ratio

207.49

Price-Earnings ratio207.49

Dividend yield

—

Dividend yield—

Average volume

963.41K

Average volume963.41K

High today

$75.09

High today$75.09

Low today

$72.40

Low today$72.40

Open price

$74.77

Open price$74.77

Volume

774.65K

Volume774.65K

52 Week high

$91.00

52 Week high$91.00

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $72.40, giving the company a market capitalization of 7.79B. It carries a P/E multiple of 207.49.

On 2026-06-06, Corcept Therapeutics(CORT) stock moved within a range of $72.40 to $75.09. With shares now at $72.40, the stock is trading 0.0% above its intraday low and -3.6% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 774.65K, versus its average volume of 963.41K.

The stock's 52-week range extends from a low of $28.66 to a high of $91.00.

CORT News

Simply Wall St 53m

Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics

In late May and early June 2026, Corcept Therapeutics reported strong overall survival data for newly approved ovarian cancer drug Lifyorli from its Phase 3 ROS...

Simply Wall St 2d

Is It Too Late To Look At Corcept Therapeutics After The Recent Share Price Surge - simplywall.st

...

TipRanks 4d

Corcept Faces Amended Qui Tam Complaint After DOJ Exit

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Robinhood Markets

Palantir Technologies

Spotify

Gilead Sciences

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.